"Drug Industry" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
That segment of commercial enterprise devoted to the design, development, and manufacture of chemical products for use in the diagnosis and treatment of disease, disability, or other dysfunction, or to improve function.
| Descriptor ID |
D004345
|
| MeSH Number(s) |
J01.576.655.750
|
| Concept/Terms |
Drug Industry- Drug Industry
- Industry, Pharmaceutic
- Industries, Pharmaceutic
- Pharmaceutic Industries
- Pharmaceutic Industry
- Industry, Drug
- Drug Industries
- Industries, Drug
- Industry, Pharmaceutical
- Industries, Pharmaceutical
- Pharmaceutical Industries
- Pharmaceutical Industry
|
Below are MeSH descriptors whose meaning is more general than "Drug Industry".
Below are MeSH descriptors whose meaning is more specific than "Drug Industry".
This graph shows the total number of publications written about "Drug Industry" by people in this website by year, and whether "Drug Industry" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 2 | 1 | 3 |
| 2008 | 1 | 1 | 2 |
| 2009 | 2 | 1 | 3 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Industry" by people in Profiles.
-
Sah BK, Ahmad F, Kumar A, Singh SK, Sachdeva RK. Catering the Need of Drug Manufacturing Standard in India: An Update to Indian Pharmacopoeia. Ther Innov Regul Sci. 2025 May; 59(3):471-488.
-
Stevenson J, Poker R, Schoss J, Campbell M, Everitt C, Holly B, Stones N, Pettis RJ, Sanchez-Felix M. Pharmaceutical and biotech industry perspectives on optimizing patient experience and treatment adherence through subcutaneous drug delivery design. Adv Drug Deliv Rev. 2024 06; 209:115322.
-
D'Angelo AB, Grov C, Johnson J, Freudenberg N. Breaking Bad Patents: Learning from HIV/AIDS to make COVID-19 treatments accessible. Glob Public Health. 2021 10; 16(10):1523-1536.
-
Davidson MB. Pioglitazone (Actos) and bladder cancer: Legal system triumphs over the evidence. J Diabetes Complications. 2016 08; 30(6):981-5.
-
Akala EO, Adesina S, Ogunwuyi O. Computer Optimization of Biodegradable Nanoparticles Fabricated by Dispersion Polymerization. Int J Environ Res Public Health. 2015 Dec 22; 13(1):ijerph13010047.
-
Fortunak JM, de Souza RO, Kulkarni AA, King CL, Ellison T, Miranda LS. Active pharmaceutical ingredients for antiretroviral treatment in low- and middle-income countries: a survey. Antivir Ther. 2014; 19 Suppl 3:15-29.
-
Davis AP, Wiegers TC, Roberts PM, King BL, Lay JM, Lennon-Hopkins K, Sciaky D, Johnson R, Keating H, Greene N, Hernandez R, McConnell KJ, Enayetallah AE, Mattingly CJ. A CTD-Pfizer collaboration: manual curation of 88,000 scientific articles text mined for drug-disease and drug-phenotype interactions. Database (Oxford). 2013; 2013:bat080.
-
Vlaar CP, Hern?ndez L. Symposium review: drug discovery, development and clinical research in academia. P R Health Sci J. 2009 Sep; 28(3):268-73.
-
Flaer PJ, Younis MZ. The Brazilian experiment: HIV drugs for all. J Health Care Finance. 2009; 36(2):90-6.
-
Younis MM, Younies H, Kisa A, Hartmann M, Hussain AA, Al-Amro A. A review of the effect of pharmaceutical firm drug announcements on stock option pricing. J Health Care Finance. 2009; 35(3):35-43.